Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 243

1.

Interleukin-6: a molecule with complex biological impact in cancer.

Lacina L, Brábek J, Král V, Kodet O, Smetana K Jr.

Histol Histopathol. 2018 Sep 4:18033. doi: 10.14670/HH-18-033. [Epub ahead of print] Review.

PMID:
30178819
2.

Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis.

Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, Leza JC, Arango C.

Schizophr Bull. 2018 Aug 28. doi: 10.1093/schbul/sby125. [Epub ahead of print]

PMID:
30169868
3.

An Integrative Approach to Neuroinflammation in Psychiatric disorders and Neuropathic Pain.

Lurie DI.

J Exp Neurosci. 2018 Aug 13;12:1179069518793639. doi: 10.1177/1179069518793639. eCollection 2018. Review.

4.

Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis.

Orlovska-Waast S, Köhler-Forsberg O, Brix SW, Nordentoft M, Kondziella D, Krogh J, Benros ME.

Mol Psychiatry. 2018 Aug 16. doi: 10.1038/s41380-018-0220-4. [Epub ahead of print]

PMID:
30116031
5.

Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis.

Gallego JA, Blanco EA, Husain-Krautter S, Madeline Fagen E, Moreno-Merino P, Del Ojo-Jiménez JA, Ahmed A, Rothstein TL, Lencz T, Malhotra AK.

Schizophr Res. 2018 Jul 16. pii: S0920-9964(18)30436-5. doi: 10.1016/j.schres.2018.07.019. [Epub ahead of print]

PMID:
30025760
6.

Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis.

Romeo B, Brunet-Lecomte M, Martelli C, Benyamina A.

Int J Neuropsychopharmacol. 2018 Sep 1;21(9):828-836. doi: 10.1093/ijnp/pyy062.

7.

Gabrb2-knockout mice displayed schizophrenia-like and comorbid phenotypes with interneuron-astrocyte-microglia dysregulation.

Yeung RK, Xiang ZH, Tsang SY, Li R, Ho TYC, Li Q, Hui CK, Sham PC, Qiao MQ, Xue H.

Transl Psychiatry. 2018 Jul 17;8(1):128. doi: 10.1038/s41398-018-0176-9.

8.

Impact of antipsychotic treatment on methylation status of Interleukin-6 [IL-6] gene in Schizophrenia.

Venugopal D, Shivakumar V, Subbanna M, Kalmady SV, Amaresha AC, Agarwal SM, Narayanaswamy JC, Banerjee M, Debnath M, Venkatasubramanian G.

J Psychiatr Res. 2018 Sep;104:88-95. doi: 10.1016/j.jpsychires.2018.07.002. Epub 2018 Jul 7.

PMID:
30005373
9.

Role of Novel Dietary Supplement N-acetyl Cysteine in Treating Negative Symptoms in Schizophrenia: A 6-Month Follow-up Study.

Tharoor H, Mara S, Gopal S.

Indian J Psychol Med. 2018 Mar-Apr;40(2):139-142. doi: 10.4103/IJPSYM.IJPSYM_322_17.

10.

Salivary Inflammatory Markers in Trichotillomania: A Pilot Study.

Grant JE, Chamberlain SR.

Neuropsychobiology. 2017;76(4):182-186. doi: 10.1159/000489865. Epub 2018 Jun 19.

11.

Immunological Characteristics of Schizophrenia.

Rubesa G, Gudelj L, Makovac D.

Psychiatr Danub. 2018 Jun;30(Suppl 4):180-187.

12.

Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients - A randomized controlled trial.

Ding N, Li Z, Liu Z.

Neurosci Lett. 2018 Aug 10;681:68-72. doi: 10.1016/j.neulet.2018.05.030. Epub 2018 May 28.

PMID:
29852208
13.

Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders.

Tavakoli-Ardakani M, Abbaspour H, Farhadi Nasab A, Mazaheri Meibodi A, Kheradmand A.

Iran J Pharm Res. 2018 Winter;17(Suppl):122-129.

14.

Plasma cytokines in minimally treated schizophrenia.

Kalmady SV, Shivakumar V, Jose D, Ravi V, Keshavan MS, Gangadhar BN, Venkatasubramanian G.

Schizophr Res. 2018 Sep;199:292-296. doi: 10.1016/j.schres.2018.04.022. Epub 2018 Apr 26.

PMID:
29705005
15.

Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?

Khoury R, Nasrallah HA.

Schizophr Res. 2018 Sep;199:31-38. doi: 10.1016/j.schres.2018.04.017. Epub 2018 Apr 25. Review.

PMID:
29703661
16.

Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.

Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY, Zhao J.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jul 13;85:69-76. doi: 10.1016/j.pnpbp.2018.04.004. Epub 2018 Apr 17.

PMID:
29678772
17.

Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.

Chiappelli J, Notarangelo FM, Pocivavsek A, Thomas MAR, Rowland LM, Schwarcz R, Hong LE.

Neuropsychopharmacology. 2018 Jul;43(8):1675-1680. doi: 10.1038/s41386-018-0038-4. Epub 2018 Feb 27.

PMID:
29520060
18.

TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia.

Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ.

Schizophr Res. 2018 Sep;199:281-284. doi: 10.1016/j.schres.2018.02.048. Epub 2018 Feb 28.

PMID:
29499967
19.

Elevated levels of C-reactive protein and IL-6 among the antipsychotic medicating schizophrenia patients of Siliguri, West Bengal, India.

Gurung J, Chamlagai D, Bera NK, Chaudhuri TK, Singh B.

Nord J Psychiatry. 2018 May;72(4):311-317. doi: 10.1080/08039488.2018.1441438. Epub 2018 Feb 21.

PMID:
29464976
20.

Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study).

Strzelecki D, Urban-Kowalczyk M, Wysokiński A.

Hum Psychopharmacol. 2018 Mar;33(2):e2652. doi: 10.1002/hup.2652. Epub 2018 Feb 7.

PMID:
29417623

Supplemental Content

Loading ...
Support Center